Genomics

Dataset Information

MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer [ChIP-seq]


ABSTRACT: MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer [ChIP-seq]

PROVIDER: PRJNA1130939 | ENA |

REPOSITORIES: ENA